GSK plc (GSK) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $4.9B | $2.6B | $5.6B | $6.7B | $6.7B | $6.0B | $6.2B |
| EPS (Diluted) | $2.40 | $1.24 | $2.72 | $3.27 | $3.31 | $2.94 | $3.07 |
| YoY Growth | — | -47.7% | +117.1% | +19.7% | +0.5% | -11.4% | +3.8% |
| Net Margin | 16.2% | 8.2% | 17.5% | 16.9% | 17.0% | 16.9% | 16.7% |
| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $32.0B | $39.6B | $39.6B | $35.3B | $37.0B |
| Net Income | $5.6B | $6.7B | $6.7B | $6.0B | $6.2B |
| EPS (Diluted) | $2.72 | $3.27 | $3.31 | $2.94 | $3.07 |
| Free Cash Flow | $5.8B | $7.4B | $7.3B | $6.4B | $6.6B |
Forecast is usable, but expect normal estimate drift around earnings and macro events.
GSK plc's projected EPS for the next fiscal year is $3.27. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 55/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for GSK plc: Bear case $26, Base case $53, and Bull case $87. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
GSK plc's projected revenue growth for the next fiscal year is 24.0%, reaching approximately $39.6B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 55/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Stable margins provide a consistent baseline. No forecast model is perfect — always cross-reference with your own analysis.
GSK plc's forward operating margin is estimated at 21.1% for the next fiscal year. The margin trend is currently "stable". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($26) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is below Wall Street consensus with a 32.2% gap. For FY+1, analyst estimates blend with our model at 23% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.